Group 1 - The meeting of the fourth supervisory board of Zhejiang Dongya Pharmaceutical Co., Ltd. was held on May 30, 2025, in accordance with relevant laws and regulations [1][2] - The supervisory board approved the proposal to postpone the investment project funded by convertible bonds, stating that the decision was made based on the actual situation of the project and did not harm the interests of shareholders or the company [1][2] - The voting results showed unanimous support for the proposal, with 3 votes in favor and no votes against or abstentions [2]

东兴证券股份有限公司(以下简称"东兴证券"或"保荐机构")作为浙江东亚 药业股份有限公司(以下简称"东亚药业"、"上市公司"或"公司")向不特定对象发 行可转换公司债券的保荐机构,根据《证券发行上市保荐业务管理办法》《上海 证券交易所股票上市规则》《上市公司监管指引第2号 -- 上市公司募集资金管 理和使用的监管要求》、《上海证券交易所上市公司自律监管指引第 11 号 -- 持 续督导》等有关法律法规的要求,就东亚药业可转换公司债券募集资金投资项目 延期的事项进行了审慎核查,并发表意见如下: 一、募集资金基本情况 东兴证券股份有限公司 关于浙江东亚药业股份有限公司 可转换公司债券募集资金投资项目延期的核查意见 根据中国证券监督管理委员会《关于同意浙江东亚药业股份有限公司向不特 定对象发行可转换公司债券注册的批复》(证监许可（2023）1165 号),公司获 准向不特定对象发行可转换公司债券 690 万张,每张面值为人民币 100.00 元, 募集资金总额为人民币 69,000 万元,扣除发行费用人民币(不含增值税)981.56 万元后,实际募集资金净额为人民币 68,018.44 万元。本次发行募集资金已于 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2025 年 5 月 30 日，浙江东亚药业股份有限公司（以下简称"公司"）召开了 第四届董事会第八次会议、第四届监事会第七次会议，分别审议通过了《关于可 转换公司债券募集资金投资项目延期的议案》，主要内容如下： 浙江东亚药业股份有限公司 关于可转换公司债券募集资金投资项目延期的公告 一、可转换公司债券募集资金基本情况 | 证券代码：605177 | 证券简称：东亚药业 | 公告编号：2025-029 | | --- | --- | --- | | 债券代码：111015 | 债券简称：东亚转债 | | | 项目名称 | | 项目投资 | 募集资金 | 累计投入募集 | 累计投入 | | --- | --- | --- | --- | --- | --- | | | | 规模 | 拟投资额 | 资金金额 | 进度 | | 特色新型药物制剂研发与生 产基地建设项目（一期） | | 43,893.00 | 35,000.00 | 27,857.72 | 79.59% | | 年产 3 ...

| 证券代码：605177 | 证券简称：东亚药业 | 公告编号：2025-028 | | --- | --- | --- | | 债券代码：111015 | 债券简称：东亚转债 | | 浙江东亚药业股份有限公司 第四届监事会第七次会议决议公告 本公司监事会及全体监事保证本公告内容不存在虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 浙江东亚药业股份有限公司（以下简称"公司"）第四届监事会第七次会议于 2025 年 5 月 30 日（星期五）在浙江省台州市临海市台州湾经济技术开发区东海第五大道 21 号二楼会议室五以现场表决的方式召开，本次会议通知已于 2025 年 5 月 23 日通过邮件 的方式送达公司全体监事。 本次会议由监事会主席徐菁女士主持，会议应参加表决监事 3 人，实际参加表决 监事 3 人。本次会议的召集、召开符合《中华人民共和国公司法》等法律、法规和 《公司章程》的有关规定。 二、监事会会议审议情况 （一）审议通过《关于可转换公司债券募集资金投资项目延期的议案》 监事会认为：公司本次对募投项目进行延期是根据募投项目的实际情况做出的 ...

SHANGHAI ONE ONE III.IIAZUI 68 Yin Chena Road Middle 858881 Hinkelogic more 上海市通力律师事务所关于浙江东亚药业股份有限公司 2024 年年度股东大会的法律意见书 致:浙江东亚药业股份有限公司 上海市通力律师事务所(以下简称"本所")接受浙江东亚药业股份有限公司(以下简称 "公司")的委托,指派本所夏青律师、茹秋乐律师(以下简称"本所律师")根据《中华人民 共和国公司法》《中华人民共和国证券法》等法律、法规和规范性文件(以下统称"法律法 规")及《浙江东亚药业股份有限公司章程》(以下简称"公司章程")的规定就公司 2024年 年度股东大会(以下简称"本次股东大会")相关事宜出具法律意见。 本所律师已经对公司提供的与本次股东大会有关的法律文件及其他文件、资料予以了 核查、验证。在进行核查验证过程中,公司已向本所保证,公司提供予本所之文件中的所有 签署、盖章及印章都是真实的,所有作为正本提交给本所的文件都是真实、准确、完整和有 效的,且文件材料为副本或复印件的,其与原件一致和相符。 在本法律意见书中,本所仅对本次股东大会召集和召开的程序、 ...

| 证券代码：605177 | 证券简称：东亚药业 | 公告编号：2025-027 | | --- | --- | --- | | 债券代码：111015 | 债券简称：东亚转债 | | 浙江东亚药业股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 | 1、出席会议的股东和代理人人数 | 75 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 59,529,765 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 51.8824 | (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 (一) 股东大会召开的时间：2025 年 5 月 20 日 (二) 股东大会召开的地点：浙江省台州市临海市台州湾经济技术开发区东海 第五大道 21 号二楼会议室五 (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有股份 ...

Group 1 - Feilong Co., Ltd. received a project designation notification letter from a well-known domestic automobile brand, becoming a supplier for a water-side thermal management module, with expected sales revenue during the lifecycle meeting disclosure standards [1] - Hanchuan Intelligent's controlling shareholder received a warning letter from Jiangsu Securities Regulatory Bureau for failing to timely disclose a share pledge contract, which may affect the company's control and stock price [2] - Vanke A completed the redemption of the "20 Vanke 04" corporate bonds, with a redemption amount of 1.5 billion yuan and interest payment of 51.75 million yuan [3][4] Group 2 - China Shenhua reported a 4% year-on-year decline in coal sales volume for April, totaling 35.6 million tons, and a 3.9% decrease in commodity coal production [5] - Shaanxi Black Cat plans to increase capital by 600 million yuan for its wholly-owned subsidiary Xinjiang Black Cat Coal Industry to enhance its capital strength [6][7] - China National Aviation reported an 8.6% year-on-year increase in passenger turnover for April, with a 5.3% increase in passenger capacity [8][9] Group 3 - Huabei Pharmaceutical's subsidiary received approval for clinical trials of a recombinant tetanus vaccine, which is a new generation vaccine with better safety and immunogenicity [10] - China Chemical's subsidiary received a lawsuit notice related to a securities false statement liability dispute [11] - China Metallurgical Group reported a 24.9% year-on-year decline in new contract value for January to April, totaling 308.4 billion yuan [13] Group 4 - Zhongmei Energy reported a 5.8% year-on-year decline in commodity coal sales for April, totaling 21.1 million tons [14] - Huangma Technology announced a plan to reduce holdings of up to 6.26 million shares due to personal funding needs [15] - Aiyingshi proposed a cash dividend of 2.53 yuan per 10 shares for the fiscal year 2024 [16] Group 5 - Shengyi Technology's executives plan to reduce their holdings by a total of 1.49 million shares [17] - CanSino's inhaled tuberculosis vaccine received clinical trial approval in Indonesia [18] - Beidouxingtong completed the acquisition of 51% of Shenzhen Tianli Automotive Electronics Technology Co., Ltd. [19] Group 6 - Spring Airlines reported a 12.29% year-on-year increase in available capacity for April, with a total of 4.73 billion ton-kilometers [20] - Dongya Pharmaceutical's raw material drug received registration certification in South Korea [21] - Shandong Steel plans to establish a sales subsidiary with a registered capital of 20 million yuan [22] Group 7 - Caida Securities appointed Hu Hengsong as the executive vice president [23] - Aibulu's vice president resigned due to personal career planning [24] - *ST Jinguang's stock price surged amid a warning of delisting risk [25] Group 8 - Yunnan Energy Investment plans to implement a 600,000 tons/year salt production energy-saving and carbon reduction project with a total investment of 448 million yuan [27] - Hanyu Group's executives plan to reduce their holdings due to personal funding needs [28] - Jiangsu Boyun's shareholders plan to reduce their holdings by up to 971,300 shares [29] Group 9 - Hainan Airport signed a cooperation agreement with Harbin Institute of Technology (Shenzhen) to establish a joint laboratory [32] - Xiamen Tungsten New Energy plans to acquire 47% of Ganzhou Haopeng Technology Co., Ltd. [33] - Dongfang Materials announced a change in controlling shareholder due to judicial auction of shares [34] Group 10 - Jingyuan Environmental Protection's executives plan to reduce their holdings by a total of 1.176% of the company's shares [35] - China Pacific Insurance reported a 10.4% year-on-year increase in original insurance premium income for the first four months [36] - ST United is planning a major asset restructuring and has suspended trading [37] Group 11 - *ST Suwu's chairman received a notice of investigation for suspected information disclosure violations [39] - Huagong Technology's subsidiary plans to establish a joint venture [40] - Qibin Group terminated the purchase of 28.78% equity in its subsidiary [41] Group 12 - Huakang Clean signed a construction contract worth 143 million yuan with Dengfeng City General Hospital [42] - Kanghong Pharmaceutical received approval for clinical trials of a drug for postpartum depression [43] - Shengjing Micro plans to repurchase shares worth between 30 million and 50 million yuan [44] Group 13 - Shenghe Resources' subsidiary plans to acquire 100% of Peak Rare Earths Limited for 158 million Australian dollars [45] - Sinopec's controlling shareholder increased its stake by 302 million H-shares, amounting to HKD 1.232 billion [46] - Mingyang Circuit plans to repurchase shares worth between 15 million and 25 million yuan [47] Group 14 - China Oil Engineering's subsidiary won a project in Iraq worth approximately 11.538 billion yuan [48] - Chaojie Co., Ltd. announced the termination of a share transfer agreement [49]

| 证券代码：605177 | 证券简称：东亚药业 | 公告编号：2025-026 | | --- | --- | --- | | 债券代码：111015 | 债券简称：东亚转债 | | 浙江东亚药业股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，浙江东亚药业股份有限公司（以下简称"公司"）收到韩国食品药品 监督管理局（韩国 MFDS）原料药品注册证书，现就相关情况公告如下： 一、证书基本信息 企业名称：浙江东亚药业股份有限公司 地址：中国浙江省三门县浦坝港镇沿海工业城 产品名称：曲美布汀 DMF 注册号：20250509-13-B-489-16 曲美布汀具有促进胃动力不足或抑制胃动力过足的双重调节作用，可用于治 疗胃肠道运动功能紊乱引起的食欲不振、恶心、呕吐、嗳气、腹胀、腹鸣、腹痛、 腹泻便秘等症状。据相关数据显示，2024 年度马来酸曲美布汀制剂全国销售额 约为 3.72 亿元。 三、对公司的影响及风险提示 公司曲美布汀原料药获得韩国原料药品注册证书，标志着公司曲美布汀原料 药获得了在韩国的准入资格，将 ...

东亚药业(605177.SH)公告称，公司收到韩国食品药品监督管理局（韩国MFDS）原料药品注册证书，产 品名称为曲美布汀，DMF注册号为20250509-13-B-489-16。曲美布汀具有调节胃肠道运动功能紊乱的作 用，2024年度马来酸曲美布汀制剂全国销售额约为3.72亿元。该证书的获得将有助于公司拓展韩国医药 市场，并可能促进曲美布汀原料药在其他海外市场的销售。但需注意海外市场政策环境变化和 汇率波 动等因素的影响。 ...

浙江东亚药业股份有限公司 2024 年年度股东大会会议资料 证券代码：605177 证券简称：东亚药业 债券代码：111015 债券简称：东亚转债 浙江东亚药业股份有限公司 2024 年年度股东大会 会议资料 二〇二五年五月 | . | . | | | | --- | --- | --- | --- | | 1 4 | 13.0 | 1 | A | | 2024 | 年年度股东大会会议须知 1 | | | --- | --- | --- | | 2024 | 年年度股东大会会议议程 2 | | | 2024 | 年年度股东大会会议议案 4 | | | 议案 | 1： | 4 | | 关于 | 2024 年度董事会工作报告的议案 4 | | | 议案 | 2： 20 | | | 关于 | 2024 年度监事会工作报告的议案 20 | | | 议案 | 3： 25 | | | 关于 | 2024 年度独立董事履职情况报告的议案 25 | | | 议案 | 4： 26 | | | 关于 | 2024 年度财务决算报告的议案 26 | | | 议案 | 5： 34 | | | 关于 | 2024 年年度报告及其摘要的 ...